Editorial

Dear Colleague,

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2015 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD. Again in 2017 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.

CTAD 2017 will highlight the latest on trying to get these trials off the ground.

Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.

We look forward to seeing you in Boston!

Organizing Commitee

 

Paul Aisen

Paul Aisen, MD Alzheimer's Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego

Jacques Touchon

Jacques Touchon, MD, PhD University Hospital of Montpellier, France.

Bruno Vellas

Bruno Vellas, MD, PhD University Hospital of Toulouse, France.

Michael Weiner

Mike Weiner, MD University of California San Francisco (UCSF), USA